Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/CHEBI_72323
http://purl.obolibrary.org/obo/CHEBI_72323
|
|---|---|
| Preferred Name | alogliptin |
| Synonyms |
alogliptinum
C18H21N5O2
alogliptina
alogliptine
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
alogliptin
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | alogliptin
|
|---|---|
| label | alogliptin
|
| DBSynonym | syr-322
|
| ATCCode | A10BH04
|
| Definition | A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
|
| DBSalt | alogliptin benzoate
|
| has pharmacological target | |
| inhibits | |
| type | |
| has role | |
| InChIKey | InChIKey=ZSBOMTDTBDDKMP-OAHLLOKOSA-N
|
| is metabolised by | |
| AHFScode | 68:20.05
|
| Synonym | alogliptinum
C18H21N5O2
alogliptina
alogliptine
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
alogliptin
See more
See less
|
| xref |
CiteXplore:21397040
CiteXplore:23289982
CiteXplore:22106975
CiteXplore:22296609
CiteXplore:22419732
CiteXplore:23220949
CiteXplore:20040339
CiteXplore:21682833
RxList:http://www.rxlist.com/nesina-drug/patient-images-side-effects.htm
Drugs.com:http://www.drugs.com/mtm/alogliptin.html
CiteXplore:21558879
CiteXplore:21806314
CiteXplore:22249941
CiteXplore:23298374
Patent:EP1970063
ChEMBL:477721
CiteXplore:22237690
Patent:WO2010072680
Reaxys:10587993
ChEBI:72323
CiteXplore:22162539
CiteXplore:22512582
CiteXplore:22583697
Patent:US2007066635
National Drug Code Directory:64764-250-30
CiteXplore:21733058
Patent:US2009275750
CiteXplore:22832924
Patent:WO2008028914
CiteXplore:21595275
CASRN:850649-61-5
CiteXplore:21431099
CiteXplore:21205126
Wikipedia:http://en.wikipedia.org/wiki/Alogliptin
CiteXplore:22651127
CiteXplore:22429011
Wikipedia:Alogliptin
Patent:WO2009022009
CiteXplore:21595274
See more
See less
|
| CASRN | 850649-61-5
|
| prefixIRI | obo2:CHEBI_72323
|
| SMILES |
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O
CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
|
| InChI | InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
|
| DBBrand | nesina
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |